Intra Cellular Therapies, Inc. ITCI
We take great care to ensure that the data presented and summarized in this overview for Intra-Cellular Therapies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITCI
View all-
Vanguard Group Inc Valley Forge, PA9.63MShares$828 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$544 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$455 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$331 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$262 Million3.36% of portfolio
-
Invesco Ltd. Atlanta, GA2.99MShares$257 Million0.04% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.49MShares$214 Million3.06% of portfolio
-
State Street Corp Boston, MA1.86MShares$160 Million0.01% of portfolio
-
Franklin Resources Inc San Mateo, CA1.75MShares$151 Million0.04% of portfolio
-
Clearbridge Investments, LLC New York, NY1.73MShares$149 Million0.1% of portfolio
Latest Institutional Activity in ITCI
Top Purchases
Top Sells
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Transactions at ITCI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 13
2024
|
Michael Halstead President |
SELL
Open market or private sale
|
Direct |
18,714
-85.72%
|
$1,646,832
$88.54 P/Share
|
|
Nov 13
2024
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
18,714
+50.0%
|
$673,704
$36.89 P/Share
|
|
Nov 12
2024
|
Michael Halstead President |
SELL
Open market or private sale
|
Direct |
22,869
-81.61%
|
$2,035,341
$89.75 P/Share
|
|
Nov 12
2024
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
22,869
+50.0%
|
$525,987
$23.94 P/Share
|
|
Sep 30
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
246
+0.21%
|
$17,958
$73.17 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
34,396
-1.56%
|
$2,510,908
$73.03 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,396
+3.02%
|
$412,752
$12.73 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
35,604
-1.62%
|
$2,563,488
$72.85 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,604
+3.12%
|
$427,248
$12.73 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
32,699
-1.48%
|
$2,387,027
$73.22 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,699
+2.88%
|
$555,883
$17.57 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,513
-1.84%
|
$2,957,449
$73.63 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,513
+3.52%
|
$688,721
$17.57 P/Share
|
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,713
-2.08%
|
$1,680,762
$74.59 P/Share
|
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,713
+2.04%
|
$386,121
$17.57 P/Share
|
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
28,680
-2.61%
|
$2,122,320
$74.46 P/Share
|
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,680
+2.54%
|
$487,560
$17.57 P/Share
|
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
39,380
-1.78%
|
$2,953,500
$75.03 P/Share
|
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,380
+3.43%
|
$669,460
$17.57 P/Share
|
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
53,013
-1.19%
|
$4,028,988
$76.7 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1M shares |
|---|---|
| Grant, award, or other acquisition | 81.9K shares |
| Open market or private sale | 1.01M shares |
|---|